JNCE Jounce Therapeutics Inc.

3.35
+0.06  (+2%)
Previous Close 3.29
Open 3.3
Price To Book 1.23
Market Cap 110,488,484
Shares 32,981,637
Volume 21,296
Short Ratio
Av. Daily Volume 107,321
Stock charts supplied by TradingView

NewsSee all news

  1. Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

    CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers,

  2. Jounce Therapeutics Names Jacquelyn Fahey Sandell as Chief Legal Officer and Corporate Secretary

    CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers,

  3. Jounce Therapeutics to Present at Upcoming Investor Conferences in September

    CAMBRIDGE, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 data at AACR - PFS: median 6.2 months for patients with ICOS hi CD4 T cells.
JTX-2011
Solid tumors - Cancer
Phase 1 data to be presented at SITC November 8, 2019; 7am ET.
JTX-4014
Solid tumors
Phase 2 initiation announced June 18, 2019 with initial data due 2020.
Vopratelimab (JTX-2011) + ipilimumab
Non-small cell lung cancer and bladder cancer

Latest News

  1. Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

    CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers,

  2. Jounce Therapeutics Names Jacquelyn Fahey Sandell as Chief Legal Officer and Corporate Secretary

    CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers,

  3. Jounce Therapeutics to Present at Upcoming Investor Conferences in September

    CAMBRIDGE, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers,